ERBB2 and breast carcinoma: Among the reversible inhibitors, erlotinib and gefitinib are currently FDA-approved for the treatment of NSCLC harboring exon-19 deletions and activating EGFR mutations, and lapatinib is approved for metastatic HER2+ breast cancer [2].